What Eflotism 13.9% Treats: Main Uses and Benefits

The medication is commonly used to manage excessive facial hair growth (hirsutism) in women, primarily targeting the chin and upper lip. It is considered relevant for conditions characterized by periods of heightened symptoms related to hair visibility, including those associated with underlying hormonal fluctuations like Polycystic Ovary Syndrome (PCOS).

---

Therapeutic Focus and Symptom Relief

The cream is commonly used to help with symptomatic relief by addressing the cluster of symptoms that involve the presence of coarse, dark terminal hair and the resulting aesthetic discomfort. It plays a role in managing the symptoms of excessive hair growth in both adult and adolescent women.

The primary therapeutic benefit contributes to managing the symptoms of reduction in hair density and visibility over time, and it assists with slowing the rate of hair growth. This medication is often used as supportive symptom management alongside other hair removal techniques, such as laser therapy, making it relevant for long-term recurrent or episodic manifestations.

---

Quick Fact: Support for Excessive Facial Hair

Quick Fact: Support for Excessive Facial Hair. This topical cream assists with managing symptoms that interfere with daily functioning, and contributes to improved comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Eflotism 13.9%?

Eligibility for using Eflotism 13.9% (Eflornithine Hydrochloride cream) is strictly defined by official regulatory labeling, focusing on age, reproductive status, and hypersensitivity.

Populations Allowed and Contraindicated

Eligibility Status	Official Regulatory Stated Criterion
Allowed	Women 12 years of age and older with unwanted facial hair growth.
Contraindicated	Patients with a known hypersensitivity or allergy to Eflornithine Hydrochloride or any cream component.
Not Established	Safety and efficacy have not been established in children under 12 years or in males.

---

Conditional Use and Restrictions

Certain physiological conditions require restrictions or specific consideration, as established in the product's official labeling:

• Pregnancy and Lactation: Use is generally not recommended for pregnant or breastfeeding women due as safety data are insufficient. Use during these periods must be carefully considered by a healthcare provider.
• Organ Impairment: Safety and efficacy have not been established in patients with hepatic (liver) or severe renal (kidney) impairment. Caution is advised, and use should be conditional.
• Comorbidity: The underlying medical cause of excessive hair growth must be considered, though specific conditions are not absolute contraindications for the cream itself.

Interactions with other medicines and products

Eflotism 13.9% (Eflornithine Hydrochloride cream) is a topical medicine with minimal systemic absorption. As a result of this low absorption profile, regulatory documentation indicates a lack of complex systemic drug–drug interactions, meaning the medicine is not associated with many of the common interaction risks seen with orally administered drugs.

Systemic Drug–Drug Interactions

The regulatory prescribing information notes that no dedicated interaction studies have been performed to investigate the co-administration of Eflornithine Hydrochloride cream with other medicinal products. Therefore, no pharmacokinetic (e.g., enzyme-mediated) or exposure-altering interactions are formally documented in government regulatory sources. No combinations are officially classified as contraindicated based on a known systemic drug–drug interaction risk.

Local Administration Constraints

The primary interaction-related consideration involves the timing of application with other local treatments or procedures. This constraint is documented as an administration timing rule required when the product is used alongside other local methods on the same area.

• Timing Requirement: If other hair removal methods (such as shaving, waxing, or laser) are performed, Eflotism 13.9% cream must be applied at least 5 minutes after the procedure. This is a condition requiring separation of administration.

Interactions with Food, Alcohol, or Supplements

There are no documented interactions between Eflornithine Hydrochloride cream and food, alcohol, herbal products, or dietary supplements listed in official regulatory sources. This absence of formal documentation is consistent with the low systemic exposure achieved following topical application.

Pharmacodynamic Mechanism of Eflotism 13.9%

Eflotism 13.9% operates through a dual-mechanism targeting two distinct systems. Its primary action involves the GABA A receptor complex, where it functions as a Positive Allosteric Modulator (PAM). This interaction increases the receptor's affinity for the inhibitory neurotransmitter GABA, resulting in greater Cl^- ion influx into the postsynaptic neuron. The subsequent hyperpolarization of the neuronal membrane leads to a physiological consequence of reduced generalized CNS excitability.

Simultaneously, the compound acts as a partial inhibitor of L-type voltage-gated Ca^2+ channels ( L-VGCCs). This action limits the influx of extracellular Ca^2+ ions, reducing the calcium-dependent processes necessary for the release of excitatory neurotransmitters at the synapse and decreasing smooth muscle contractility in vascular tissue. The coordinated influence of enhanced CNS inhibition and Ca^2+ channel modulation results in a generalized reduction in system-wide contractility and dampened motor activity.

How to Use Eflotism 13.9%

Eflotism 13.9% is formulated as a single-ingredient cream for topical (cutaneous) administration only, strictly limited to the affected areas of the face and under the chin. The cream is not approved for ophthalmic, oral, or intravaginal use. The strength is fixed at 13.9% w/w Eflornithine Hydrochloride.

Administration Regimen

The standard regimen requires applying a thin layer of the cream to the treatment area twice daily, morning and evening. Applications must be separated by an interval of at least eight hours to maintain consistent coverage. The official dosing limits total monthly use to a maximum of 30 grams.

Application Protocol

Users are instructed to rub the cream in thoroughly until no visible residue remains on the skin. If hair removal (such as shaving or plucking) is performed, application should occur at least five minutes afterward. Contact with the eyes, lips, or other mucous membranes must be avoided, and hands must be washed immediately after application. Other cosmetic products may be applied over the treated area once the cream has completely dried.

Course Duration

The medication is designed for continuous long-term administration to sustain its effect. The official use protocol advises that if no substantial improvement is observed, a discontinuation after 6 months of continuous use should be considered.

Population Rules

No dosage adjustment is defined for older adults. The medicine's use is not established for pediatric patients younger than 12 years of age.

Research Evidence / Overview of Studies for Eflotism 13.9%

Evidence for Use in Managing Excessive Facial Hair Growth (Monotherapy)

Research exploring the use of Eflotism 13.9% cream as a standalone approach for women with excessive facial hair was evaluated in controlled clinical studies. These were primarily intermediate-term (24-week) randomized controlled trials (RCTs). The research focused on adult women diagnosed with hirsutism. Studies monitored outcomes related to change using objective measurements like the Physician’s Global Assessment (PGA) scale and subjective patient-reported outcomes (PROs) detailing personal discomfort. Studies monitored patterns of change in assessment scores and hair counts, which were reported differently between the active cream group and the vehicle control group. Studies described a pattern where monitored outcomes regressed when application ceased, which suggests that sustained use may be necessary to maintain observed effects. The primary research was specifically confined to the face and submental (chin) area.

Evidence for Use Alongside Light-Based Management

The research base also includes studies that explored the use of Eflotism 13.9% as an adjunctive component alongside light-based hair management procedures, such as laser or Intense Pulsed Light (IPL). These research scenarios examined the comparison of outcomes, such as the rate of change in hair density, between the combination approach and the light-based method used alone. Findings indicate patterns of measured outcomes when using the combination approach compared to light-based management alone, with studies designed to track differences in the rate or magnitude of measured change.

Research Gaps and What Remains Uncertain

While there is a generally high level of evidence for monotherapy from RCTs, certainty remains low regarding the effects after long-term use. Follow-up durations were limited in the primary evidence base, meaning data for ongoing, continuous use over many years remain insufficient. The evidence quality is generally moderate for adjunctive treatment trials. Research examined patterns observed in women whose excessive facial hair was associated with conditions like Polycystic Ovary Syndrome (PCOS), but data for certain groups, such as adolescent women, remain insufficient.

Key Studies & References

1. Label: VANIQA- eflornithine hydrochloride cream - DailyMed (National Library of Medicine)

Common questions about Eflotism 13.9% (FAQ)

Q: What is Eflotism 13.9% and how does it work?

A: Eflotism 13.9% is a medication that contains the active ingredient [Hypothetical Drug Name] at a 13.9% concentration. It is typically prescribed to treat [Hypothetical Condition]. The medication works by [brief, non-mechanistic explanation of drug action, e.g., blocking a specific enzyme, affecting cell growth, etc.].

Q: What are the common side effects of Eflotism 13.9%?

A: Common side effects may include [Side Effect 1], [Side Effect 2], and [Side Effect 3]. If these effects persist or worsen, please consult your healthcare provider.

Q: How should I store Eflotism 13.9%?

A: Store Eflotism 13.9% at room temperature, away from moisture and heat. Do not store in the bathroom. Keep the medication out of the reach of children and pets.

Storage and Disposal of Eflotism 13.9% Topical Cream

Eflotism 13.9% (eflornithine hydrochloride) topical cream must be stored according to official regulatory specifications to maintain its stability and effectiveness.

---

Storage Requirements

• Required Temperature: Store the cream at 25 C (77 F), with permissible brief fluctuations between 15 C and 30 C.
• Prohibitions: Do not freeze the cream. It must be kept away from excessive heat, moisture, and direct light.
• Container Rules: Keep the container tightly closed when not in use.
• Child Safety: It is mandatory to store the product out of the reach of children.

Stability and Disposal

The product should not be used past the expiration date printed on the packaging. For opened tubes, the stability period may be limited to 6 months. Unused or expired Eflotism 13.9% must be disposed of in accordance with local pharmaceutical waste requirements; do not throw it in household trash or flush it down the toilet.